{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:48:57Z","timestamp":1792514937808,"version":"4.5.0"},"reference-count":42,"publisher":"SAGE Publications","issue":"1_suppl","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100014598","name":"MannKind Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014598","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:p>\n                    In January 2006, Exubera\n                    <jats:sup>\u00ae<\/jats:sup>\n                    (Pfizer, New York, NY) became the first inhaled insulin to be approved by the U.S. Food and Drug Administration (FDA). However, Exubera was withdrawn from the market in 2007 due to low sales. Ongoing innovation in inhaled insulin led to FDA approval of Technosphere\n                    <jats:sup>\u00ae<\/jats:sup>\n                    Insulin (TI), the therapeutic component of the Afrezza\n                    <jats:sup>\u00ae<\/jats:sup>\n                    inhaled insulin delivery system (MannKind Corporation, Westlake Village, CA). Currently, TI is the only rapid-acting inhaled insulin currently available. Recent studies have demonstrated the efficacy of TI with no concerning adverse events other than mild cough, which is generally mild, transient, and diminishes over time. However, many clinicians remain cautious about the potential for adverse events with chronic use beyond the duration of closely monitored clinical trials. In this article, we address the pulmonary safety concerns that are often associated with TI and present evidence demonstrating the safety of TI in type 1 diabetes and type 2 diabetes populations.\n                  <\/jats:p>","DOI":"10.1177\/15209156251396118","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T04:16:49Z","timestamp":1770005809000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Pulmonary Safety and Clinical Considerations for Inhaled Insulin: A Comprehensive Review"],"prefix":"10.1177","volume":"28","author":[{"given":"Janet B.","family":"McGill","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Metabolism and Lipid Research, School of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar M.","family":"Mayer","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Perelman School of Medicine, The Children\u2019s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01748183"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01735830"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01748135"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.20.8.552"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/diaspect.29.3.180"},{"key":"e_1_3_3_7_2","unstructured":"Drugs.com. Afrezza FDA Approval History. Available from: https:\/\/www.drugs.com\/history\/afrezza.html?utm_source=chatgpt.com [Last accessed: June19 2025]."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2024.0581"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2024.0582"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-1832"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-0838"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623320960420"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/1932296816658055"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01500.x"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2007.0212"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2153"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.1.239"},{"issue":"1","key":"e_1_3_3_18_2","article-title":"A Phase 1, open-label, randomized dose proportionality study of Technosphere\u00ae insulin inhalation powder (TI) doses up to 80 U Administered with the Gen2 Inhaler in Healthy Subjects","volume":"62","author":"Baughman RA","year":"2013","unstructured":"Baughman RA, , Amin N, , Watkins E, et al. A Phase 1, open-label, randomized dose proportionality study of Technosphere\u00ae insulin inhalation powder (TI) doses up to 80 U Administered with the Gen2 Inhaler in Healthy Subjects. Diabetes, 2013; 62(Suppl. 1):A251 abstract 982-P. Available from: https:\/\/diabetesjournals.org\/diabetes\/article\/62\/Supplement_1\/A217\/14422\/Clinical-Diabetes-Therapeutics?searchresult=1 [Last accessed:June 4, 2025].","journal-title":"Diabetes"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01039.x"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01567.x"},{"key":"e_1_3_3_21_2","unstructured":"U.S. Food & Drug Administration. Humalog: Highlights of Prescribing Information. Available from: https:\/\/uspl.lilly.com\/humalog\/humalog.html#pi [Last accessed: June19 2025]."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040832"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/19322968211033868"},{"key":"e_1_3_3_24_2","unstructured":"MannKind Corporation. Afrezza Prescribing Information. Available from: https:\/\/afrezza.com\/wp-content\/uploads\/2023\/02\/Full-Prescribing-Information-Feb-2023.pdf [Last accessed: May19 2025]."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00958-8"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.3.590"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01368-7"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/19322968221110622"},{"key":"e_1_3_3_29_2","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research. Other Review(s). Application number 022472Orig1s000. U.S. Department of Health and Human Services. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/022472Orig1s000OtherR.pdf [Last accessed: July6 2025]."},{"key":"e_1_3_3_30_2","unstructured":"MannKind Corporation. Afrezza. Available from: https:\/\/afrezza.com\/afrezza-fast-facts\/is-afrezza-discontinued\/ [Last accessed: October15 2025]."},{"key":"e_1_3_3_31_2","unstructured":"U.S. Food & Drug Administration (FDA). FDA Adverse Event Reporting System (FAERS) Public Dashboard. Available from: https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard [Last accessed: October12 2025]."},{"key":"e_1_3_3_32_2","unstructured":"Khan M Rodriguez G Zavgorodneva Z Bahtiyar G. SAT-510. Squamous cell carcinoma of the lung in a patient using inhaled insulin: A case report and review of pulmonary safety concerns. Endocrine Society. Presented at ENDO2025 July 12-15 2025. San Francisco CA. Available from: https:\/\/www.abstractsonline.com\/pp8\/#!\/20942\/presentation\/6671 [Last accessed: October14 2025]."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.08.151"},{"key":"e_1_3_3_34_2","volume-title":"StatPearls [Internet]","author":"Altaf R","year":"2025","unstructured":"Altaf R, , Parmar M, , Dornase A. [Updated 2023 Jun 26]. In: StatPearls [Internet]. StatPearls Publishing: Treasure Island (FL); 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556018\/?utm_source=chatgpt.com. [Last accessed:June 24, 2025]."},{"key":"e_1_3_3_35_2","unstructured":"Drugs.com. Albuterol Side Effects. Available from: https:\/\/www.drugs.com\/sfx\/albuterol-side-effects.html?utm_source=chatgpt.com [Last accessed: June24 2025]."},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2017.03.005"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.698"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-14-52"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01760-5"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01084-0"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0200"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1177\/19322968251388128"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.10.2543"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15209156251396118","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15209156251396118","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15209156251396118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:15:23Z","timestamp":1777400123000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15209156251396118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":42,"journal-issue":{"issue":"1_suppl","published-print":{"date-parts":[[2026,2,1]]}},"alternative-id":["10.1177\/15209156251396118"],"URL":"https:\/\/doi.org\/10.1177\/15209156251396118","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}